Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
it's the opposite of a pump and dump! Inmed has built its value over YEARS of steady, keep-the-course management.
From the beginning, they've steadily put together a world class team of respected industry professionals, working toward a clear set of objectives that are based on extremely solid concepts. When you compare what Inmed is doing to GW Pharma, it's actually shocking to realize that Inmed has far more arrows in its quiver and many more potential revenue streams than it's 'big sister'; database & patentable biosynthesis tech, smaller physical footprint requirements/ecological advantages, compound quality/consistency advantages, compounds in development, etc.
What does GW have? Product closer to market, that's it. But with legalization sweeping across North America, and the opioid crisis in full blaze, the FDA will be pressured to fast track alternative, less addictive treatments. I predict that, in a few years, GW will be only one among many pharmas with product in the market. But Inmed has the potential to be in a class above them all.
When I think of a pump and dump, I think slick presentations and a monotonous drumbeat of 'positives' that amount to not much overall. In Inmed's case, there's been very little done in branding and positioning. Retaining a PR agency is the only move they've made, but the news has been steady and restrained. Public awareness is still statistically 0% :)
I'll hold for a 100 bagger :)
Speechless here...
Uplifting to NASDAQ would be an insane booster...
massive volume day... past 10 day average already with 4 hours to go
won't be long before we punch through that resistance level, hopefully
At those targets exit strategy is going to become a tough topic very soon...
we're set up for a crack of a start! GLTA this year, may we all retire soon :)
Who is a patent expert here?
Can anyone chime in on what it takes to convert the provisional biosynthesis patent to a permanent one?
talk to me about this Ichimoku cloud - what am I looking at?
I could do with a bit less noise too. But on the other hand, I appreciate the nuggets of info hidden between the dollar signs ;)
I'm perfectly satisfied with closing out the year at $1 and kicking off 2018 with another gap up :)
Thanks for chiming in, and congrats on doubling your investment! Good luck for 2018.
if I'm not mistaken you've been a long-term long as well, right? Congrats to all, and here's to a blistering 2018!
ok you can stop the pump now, friend...
burn :)
my new year's hope: reaching $2 per share and avoiding any need for a reverse split for an uplisting.
Watch out for a triple top: https://www.investopedia.com/university/charts/charts9.asp
I know we’re all excited about recent upswings and volume (I am too), but when I look at the charts I’m seeing a mix of signals across various time frames. Long term patterns look good, but there’s a bit of noise in the mid term. A stop loss wouldn’t be out of place, especially if you can have it trigger a fresh buy at an even lower strike
Told ya last week the charts were looking good... now past .62! :(
noticed that too, but not too concerned. Putting faith in the fact that the weekly KST shows a nice cross over, which bodes well, especially since the bottom was already deep in positive territory :)
I run charts with a variety of indicators, but in particular I like Pring's Special K and KST for how they smooth out averages and make it easier to see momentum across various timeframes...
Where Inmed's concerned, to my eyes it looks like this rally is out of steam. 15, hourly and 4H charts seem to indicate we may be looking at some sideways or lower markets for a bit, but the long term trend lines (weekly charts) make me quite happy!
I'm perfectly fine with settling into a new base level in the mid-50's. That's a solid 100% above where we were 3 months ago, and a great jumping off point for another gap up.
My confidence in Inmed is built on their achievements over the last 3 years, and even at the time I invested it was built on early signals... Was there gut involved? Only in plonking down hard earned cash for a near-invisible OTC stock! :)
nope, you got it... Inmed is well on its way to securing their process through patent protection, they've been steadily building out their team over the last 18 months to prep for scaling, and have their own compounds in the pipeline as well.
BUT - We're still seeing a lot of the market focusing on 1st generation cannabis plays; growers, equipment vendors, and a few 'competitors' in biotech who rely on farmed resource material. Obviously GW is the big kahuna in that regard, having made a name for itself in the mainstream. But much of the weed investing world is still on the fringes of general public awareness.
Inmed is a gen 2 cannabis company, however. They had metalevel vision to see the future of the market evolving, developing in a certain direction, and very early on anticipated the need that direction would create. I firmly believe that their tech has the potential to be a weed gen 1 company killer. Being able to produce stable, quality controlled compounds, with a lower geographical and environmental impact compared to farms is potentially HUGE (see insulin)
Historically (pre 2017), Inmed seems to have focused purely on meeting internal milestones, with little concern about building public awareness. Over the last year, though, we've seen the impact of the addition of a PR/News agent to push Inmed's succcesses to the fore. This can be recognized in the amount of new money flowing into the ticker, and the volume steadily creeping up over the year.
BUT - we're still very much on the fringes here; OTCBB is unappealing/invisible to a large majority of retail investors, and institutional investors typically can't/don't get involved until market cap is well above where we stand now.
So, we're not 'there' yet; Inmed has done exceptionally well at putting together a string of news hits without an "oh shit!" moment (remember when GW announced they couldn't validate the accuracy of their books after their uplisting? I remember that 50+% haircut). But there's still a long road to go before we're in ten-bagger or more territory here...
I have strong confidence that the team will continue to steadily build value for shareholders. Engaging an external auditor is a recent positive signal, and there are plenty of announcements that could make 2018 an exciting year. Big shifts in value will come through events like signing big partnerships, more marquee hires, ramping up production, moving to a more visible/reputable exchange, etc.
Personally I've held Inmed for the last 3 years or so, averaging down and accumulating where I could (never enough though!). I'm not in it to make a quick buck, nor do I trade the short term swings in value... I'm just sitting back, slowly watching my money tsunami get ready to come ashore :)
if you need supporting evidence for the importance/value of biosynthesis in the production of cannabinoid pharmaceuticals, this is an interesting read: http://cannabissafetyinstitute.org/wp-content/uploads/2015/06/Microbiological-Safety-Testing-of-Cannabis.pdf
That’s easily accomplished by doing a reversed split, like GW did when they uplisted (I believe it was an 8:1)
I believe it ran up to the 70’s when they announced the Eli Lily hire
I've been enjoying the ride to tenbagger silently ;)
While I'm not as deeply researched, based on what I know I have to agree with PharmaGreen here. IMLFF seems to be exhibiting the right elements of an early stage sustainable business being built on the combination of a rapid development platform and the pursuit of specific therapeutic compounds.
I'm long on them in the hope that, at some point, pipeline successes will hockeystick this stock into dollar territory at some point.
Yesterday's drop, coming after fair to middling results at the presentation in NYC, leads me to conclude the spotlight has moved on from GWPH, and from pot stocks in general. 6 months ago, similar reports would have boosted values incongruously. Now that the first major legalization battles are over and done with the only big momentum triggers I see for GW are federal-level reclassification (not in the company's control) and big hits in the FDA approval process for pipelined candidates (partially in the company's control). The honeymoon is over, it's time to deliver real business results.
Any news/updates from the CEOs speech at the conference this week?
premarket action seems to indicate you might be right :)
interesting to see CANLF getting some airtime.... I loaded up there as well recently. Will be long them as much as I've been long GWPH
hold hold hold... reduced MS price target seemed to me to be a coy play to impact price downward.
I do think that soon enough the pot bubble will pop. Some of that shakeout will impact GWPH, but in the end I keep coming back to the reason I bought into this company years ago: there simply isn't anyone else out there doing the same thing. There's still plenty in the pipe to deliver good news through the second half of the year, and GW is rapidly becoming a split or takeover target.
For the time being there will be some dips, especially around earnings, but this thing has a lot of leg left.
yes, please do that often and in bulk :)
Thanks for that link. Cool to see the other potential GW therapies in the pipeline, and where they stand:
http://clinicaltrials.gov/ct2/results?term=GWP
you and me both... what a ride this is!
welcome to your new all time high, GWPH. Boom goes the dynamite! :)
awesome overview, and great visualization of the potential upside in the owned/unpartnered space.
defensive & upside tips?
I see all of you adventurers actively trading this stock, and no doubt reaping solid benefits from the swings in price. Personally I've always been a fairly passive investor. Lately though, I've been reading up on options trading, but have not reached a level of comfort sufficient enough to dip my toes in the water.
To help educate me further, I figured a practical challenge might help generate some interesting insights/trading ideas, so consider this:
- I currently hold 200 shares at 14/share
- I've sold a small stake to cover my original purchase price, so it could drop to zero and I'd be whole. that doesn't mean I didn't feel the sting of seeing it drop into the 40's, though...
- I'm concerned about both having the bottom drop out AND/OR missing the Big Run Up
With the above info, I'm curious to know what your ideas would be for a more active strategy to leverage my stake in protecting what's there, and potentially generating additional returns. What would you do?